New research shows that the the longest-acting injectable PrEP, shows no adverse interactions with hormone therapy for trans ...

Compounding that statistic, prior studies indicate some trans people at high risk for HIV transmission are hesitant to take ...

Match Health Collective today announced the launch of Pulse Health Sciences ("Pulse"), a new medical education and insights division co-founded by Jackson Choy, who will serve as President. Pulse ...

The FDA contacted J&J right after ASH to discuss using a special fast pass on a multiple myeloma regimen. Elsewhere, a new ...

Gilead said its once-daily bictegravir/lenacapavir tablet met non-inferiority vs Biktarvy in phase III ARTISTRY-2, paving the way for filings.

With a second late-stage trial win for its investigational HIV combo in the books, Gilead Sciences is moving full steam ahead ...

The submission is based on outcomes from the Phase III DELTA Teen trial of Anzupgo (delgocitinib) 20mg/g cream.

In today's economic landscape, where inflation and rising interest rates are a constant concern, companies are compelled to prioritize efficiency and cash flow management. This focus is essential not ...